Control-Oriented Models Inform Synthetic Biology Strategies in CAR T Cell Immunotherapy
Preprint
Abstract
Chimeric antigen receptor (CAR) T cell therapy is revolutionizing the treatment of blood cancers. Mathematical models that can predict the effectiveness of immunotherapies such as CAR T are of increasing interest due to their ability to reduce the number of experiments performed and to guide the theoretical development of new therapeutic strategies. {Following this rationale, we propose the use of control-oriented models to guide the augmentation of CAR T therapy with synthetic gene circuitry. Here we present an initial investigation where we adapt a previously developed CAR T model for control-oriented purposes. We then explore the impact of realistic alternative activation methods as control inputs to ensure effective tumor clearance.Keywords
All Related Versions
This publication has 14 references indexed in Scilit:
- CAR immune cells: design principles, resistance and the next generationNature, 2023
- Synthetic cytokine circuits that drive T cells into immune-excluded tumorsScience, 2022
- Cellular kinetics: A clinical and computational review of CAR-T cell pharmacologyAdvanced Drug Delivery Reviews, 2022
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell ResponsesCell, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Rewiring T-cell responses to soluble factors with chimeric antigen receptorsNature Chemical Biology, 2018
- Chimeric antigen receptor T-cell therapies for lymphomaNature Reviews Clinical Oncology, 2017
- Optimization and Control of Agent-Based Models in Biology: A PerspectiveBulletin of Mathematical Biology, 2016
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing CircuitsCell, 2016
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences, 1989